

3. Literatur:

1. Sarcoma Meta-analysis Collaboration: Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. *Cochrane Database Syst Rev* 4, 2000
2. Frustaci S, Gherlinzoni F, De Paoli A, et al: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. *J Clin Oncol* 19:1238-1247, 2001
3. Eggermont AM, Schraffordt Koops H, Klausner JM, et al: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. *Ann Surg* 224:756-764, 1996
4. Eilber FC, Rosen G, Eckardt J, et al: Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. *J Clin Oncol* 19:3203-3209, 2001
5. DeLaney TF, Spiro IJ, Suit HD, et al: Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. *Int J Radiat Oncol Biol Phys* 56:1117-1127, 2003
6. Wendtner CM, Abdel-Rahman S, Krych M, et al: Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. *J Clin Oncol*. 20:3156-3164, 2002
7. Hohenberger P, Allenberg J R, Schlag P M, **Reichardt P**: Results of surgery and multimodal therapy for patients with soft tissue sarcoma invading to vascular structures. *Cancer* 85:396-408, 1999
8. Van Glabbeke M, van Oosterom AT, Nielsen OS, et al: Prognostic factors for 1st line high dose chemotherapy outcome in advanced soft tissue sarcoma: an overview of 759 patients included in studies of the EORTC Soft Tissue and Bone Sarcoma Group. *Proc Am Soc Clin Oncol* 17:512a, 1998
9. **Reichardt P**, Van Glabbeke MM, Mouridsen HT, et al: Influence of locally advanced and recurrent disease on survival of patients with advanced soft tissue sarcomas. A retrospective analysis of the EORTC Soft Tissue and Bone Sarcoma Group. *Proc Am Soc Clin Oncol* 20:354a, 2001
10. Bramwell VHC, Mouridsen HT, Santoro A, et al: Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. *Eur J Cancer Clin Oncol* 23:311-321, 1987

11. van Oosterom AT, Mouridsen HT, Nielsen OS, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. *Eur J Cancer* 38:2397-406, 2002
12. Mouridsen HT, Bastholt L, Somers R, et al: Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer Clin Oncol* 23:1477-1483, 1987
13. Nielsen OS, Dombernowsky P, Mouridsen H, et al: High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC Soft Tissue and Bone Sarcoma Group. *Br J Cancer* 78:1634-1639, 1999
14. Judson I, Radford JA, Harris M, et al: Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 37:870-877, 2001
15. Verweij J, Lee SM, Ruka W, et al: Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. *J Clin Oncol* 18:2081-2086, 2000
16. Borden EC, Amato DA, Rosenbaum C, et al: Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. *J Clin Oncol* 5:840-850, 1987
17. **Reichardt P**, Tilgner J, Mrozek A, Dörken B: Continuous infusion of DTIC in heavily pretreated patients with metastatic soft tissue sarcoma. *Proc Am Soc Clin Oncol* 19:564a, 2000
18. Elias AD, Eder JP, Shea T, et al: High-dose ifosfamide with mesna uroprotection: a phase I study. *J Clin Oncol* 8:95-103, 1990
19. Le Cesne A, Antoine E, Spielmann M, et al: High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. *J Clin Oncol* 13:1600-1608, 1995
20. **Reichardt P**, Tilgner J, Sachs U, et al: High-dose ifosfamide in heavily pretreated patients with bone and soft tissue sarcoma. *Ann Hematol* 73 (Suppl 2):A100, 1996
21. **Reichardt P**, Tilgner J, Mrozek A, Hohenberger P, Dörken B. High-dose ifosfamide for heavily pretreated patients with bone and soft tissue sarcomas: a report on two consecutive phase II – studies using different

- doses and schedules. 4th Annual Scientific Meeting of the Connective Tissue Oncology Society, Vancouver, Canada, 1998
22. Blomquist C, Wiklund T, Pajunen M, Virolainen M, Elomaa I: Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma. *Cancer Chemother Pharmacol* 36:263-265, 1995
 23. Kollmannsberger C, Brugger W, Hartmann JT, et al: Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. *Anti Cancer Drugs* 10:453-456, 1999
 24. Hartmann JT, Oechsle K, Mayer F, Kanz L, Bokemeyer C. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. *Anticancer Res* 23:1899-1901, 2003
 25. Nielsen OS, **Reichardt P**, Pink D, et al: An EORTC phase I study to determine the safety of combined caelyx and ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. *Eur J Cancer* 1 (Suppl. 5):209, 2003
 26. Balcerzak SP, Benedetti J, Weiss GR, Natale RB. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study. *Cancer* 76:2248-2252, 1995
 27. Casper ES, Waltzman RJ, Schwartz GK, et al: Phase II trial of paclitaxel in patients with soft tissue sarcoma. *Cancer Invest* 16:442-446, 1998
 28. Sutton G, Blessing JA, Ball H. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study. *Gynecol Oncol* 74:346-349, 1999
 29. Fata F, O'Reilly E, Ilson D, et al: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. *Cancer* 86:2034-2237, 1999
 30. van Hoesel QG, Verweij J, Catimel G, et al: Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. *Ann Oncol* 5:539-542, 1994
 31. Amodio A, Carpano S, Paoletti G, et al: Phase II study of docetaxel in patients with advanced stage soft tissue sarcoma. *Clin Ter* 149:121-125, 1998
 32. Kostler WJ, Brodowicz T, Attems Y, et al: Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. *Ann Oncol* 12:1281-1288, 2001
 33. Patel SR, Gandhi V, Jenkins J, et al: Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. *J Clin Oncol* 19:3483-3489, 2001

34. Svancarova L, Blay JY, Judson IR, et al: Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 38:556-559, 2002
35. Okuno S, Ryan LM, Edmonson JH, Priebat DA, Blum RH. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. *Cancer* 97:1969-1973, 2003
36. Bramwell VH, Eisenhauer EA, Blackstein M, Boos G, Knowling M, Jolivet J, Bogues W. Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. *Ann Oncol* 6:847-849, 1995
37. Budd GT, Rankin C, Hutchins LF, Wong L, Petruska PJ, Antman K. Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. *Southwest Oncology Group. Invest New Drugs* 20:129-132, 2002
38. **Reichardt P**, Oechsle K, Pink D, Bokemeyer C, Schneller F, Issels R, Kanz L, Hartmann J T. An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. *Invest New Drugs* 21:481-486, 2003
39. **Reichardt P**. Chemotherapy of soft tissue sarcoma. *J Cancer Res Clin Oncol* 128 (Suppl. 1):26, 2002
40. Bramwell VHC. Chemotherapy for metastatic soft tissue sarcomas - Another full circle? *Br J Cancer* 64:7-9, 1991
41. Blay JY, van Glabbeke M, Nielsen OS, et al: Five-year survivors in patients (pts) with advanced soft tissue sarcoma (ASTS) treated with doxorubicin: A study on 1742 patients. *Proc Am Soc Clin Oncol* 17:512a, 1998
42. Schoenfeld DA, Rosenbaum C, Horton J, et al. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. *Cancer* 50:2757-2762, 1982
43. Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. *Cancer* 52:626-632, 1983
44. Borden EC, Amato DA, Edmonson JH, Ritch PS, Shiraki M. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. *Cancer* 66:862-867, 1990
45. Edmonson JH, Ryan LM, Blum RH, et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. *J Clin Oncol* 11:1269-1275, 1993

46. Santoro A, Tursz T, Mouridsen H, et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *J Clin Oncol* 13:1537-1545, 1995
47. Tursz T, Verweij J, Judson I, et al: Is high-dose chemotherapy of interest in advanced soft tissue sarcomas ? An EORTC randomized phase III trial. *Proc Am Soc Clin Oncol* 15:337, 1996
48. Antman K, Crowley J, Balcerzak SP et al: An Intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. *J Clin Oncol* 11:1276-1285, 1993
49. Jelic S, Kovcin V, Milanovic N, et al: Randomized study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. *Eur J Cancer* 33:220-225, 1997
50. Benjamin RS: Grade 3 nausea, vomiting, and myelosuppression or progressive, metastatic sarcoma? *J Clin Oncol* 5:881-889, 1987
51. Mansi JL, Fisher C, Wiltshaw E, et al: A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. *Eur J Cancer Clin Oncol* 24:1439-1443, 1988
52. Schütte J, Mouridsen HT, Steward W, et al: Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. *Eur J Cancer* 26:558-561, 1990
53. Loehrer PJ, Sledge GW, Nicaise C, et al: Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase III trial. *J Clin Oncol* 7:1655-1659, 1989
54. Weh HJ, Zügel M, Wingberg D, et al: Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. *Onkologie* 13:448-452, 1990
55. Steward WP, Verweij J, Somers R, et al: Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organisation for Research and Treatment of Cancer soft tissue and bone sarcoma group. *J Clin Oncol* 11:15-21, 1993
56. Patel SR, Vadhan-Raj S, Burgess MA, et al: Dose intensive therapy does improve response rates - updated results of adriamycin and ifosfamide with growth factors in patients with untreated soft tissue sarcomas. *Proc Am Soc Clin Oncol* 16:499a, 1997

57. Frustaci S, Foladore S, Buonadonna A, et al: Epirubicin and ifosfamide in advanced soft tissue sarcomas. *Ann Oncol* 4:669-672, 1993
58. Toma S, Palumbo R, Canavese G, et al: Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. *Cancer Chemother Pharmacol* 31 (Suppl 2):222-227, 1993
59. Chevallier B, Leyraz S, Olivier JP, et al: Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study. *Cancer Invest* 11:135-139, 1993
60. Frustaci S, Buonadonna A, Galligioni E, et al: Increasing 4'-Epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study. *J Clin Oncol* 15:1418-1426, 1997
61. **Reichardt P**, Tilgner J, Hohenberger P, Dörken B: Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. *J Clin Oncol* 16:1438-1443, 1998
62. Elias AD, Ayasj LJ, Eder JP, et al: A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. *J Clin Oncol* 9:320-327, 1991
63. Dumontet C, Biron P, Bouffet E, et al: High dose chemotherapy with ABMT in soft tissue sarcomas: A report of 22 cases. *Bone Marrow Transpl* 10:405-408, 1992
64. Kessinger A, Petersen K, Bishop M, Schmit-Pokorny K. High dose therapy with autologous hematopoietic stem cell rescue for patients with metastatic soft tissue sarcoma. *Proc Am Soc Clin Oncol* 13:480, 1994
65. Mesia R, Sola C, Tabernero JM, et al. High dose chemotherapy with autologous bone marrow rescue in metastatic sarcomas. *Ann Oncol* 5 (Suppl 8):178, 1994
66. Bokemeyer C, Franzke A, Hartmann JT, et al: A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. *Cancer* 80:1221-1227, 1997
67. Blay JY, Bouhour D, Ray-Coquard I, Dumontet C, Philip T, Biron P. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. *J Clin Oncol* 18:3643-3650, 2000
68. Rosti G, Philip T, Chauvin F, et al. European Group for Blood and Marrow Transplantation (EBMT) registry in solid tumors: 12 years of experience. *Bone Marrow Transplant* 17(Suppl 1):106, 1996

69. **Reichardt P**, Verweij J, Crowther D. Should high-dose chemotherapy be used in the treatment of soft tissue sarcoma? *Eur J Cancer* 33:1351-1360, 1997
70. **Reichardt P**. High-dose chemotherapy in adult soft tissue sarcoma. *Crit Rev Oncol Hematol* 41:157-167, 2002
71. **Reichardt P**, Tilgner J, Mrozek A, Breitschaft A, Maschmeyer G, Dörken B. High-dose therapy in soft tissue sarcomas. In: Schultze W (Editor): High-dose therapy and transplantation of haematopoietic stem cells. Blackwell Wissenschafts-Verlag, Berlin, Wien, 2000
72. **Reichardt P**, Pink D, Tilgner J, Kretschmar A, Thuss-Patience P C, Dörken B. Oral Trofosfamide: An active and well tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis. *Onkologie* 25:541-546, 2002
73. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. *J Clin Oncol* 20:2824-2831, 2002
74. **Reichardt P**, Lindner T, Pink D, Thuss-Patience P C, Kretschmar A, Dörken B. Chemotherapy in alveolar soft part sarcoma: What do we know? *Eur J Cancer* 39:1511-1516, 2003
75. Kindblom L-G, Meis-Kindblom J, Bümming P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST) – a population-based study of 600 cases. *Ann Oncol* 13 (Suppl.5):157, 2002
76. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-Function Mutations of c-kit in Human Gastrointestinal Stromal Tumors. *Science* 279:577-580, 1998
77. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. *Ann Surg* 231:51-58, 2000
78. Edmonson JH, Marks RS, Buckner JC, Mahoney MR. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. *Cancer Invest* 20:853-854, 2002
79. **Reichardt P**, Pink D, Hohenberger P. Paradigmenwechsel in der Therapie gastrointestinaler Stromatumoren. *Der Onkologe* 8:378-383, 2002
80. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. *N Engl J Med* 344:1052-1056, 2001

81. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 347:472-480, 2002
82. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. *Lancet* 358:1421-1423, 2001
83. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J Clin Oncol* 21:4342-4349, 2003
84. Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. *Proc Am Soc Clin Oncol* 22:814, 2003
85. Verweij J, Casali PG, Zalcberg J, Le Cesne A, **Reichardt P**, Blay J-Y, et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): Interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. *Proc Am Soc Clin Oncol* 22:814, 2003
86. **Reichardt P**, Schneider U, Stroszcynski C, Pink D, Hohenberger P. Histological response pattern of gastrointestinal stromal tumor following treatment with tyrosine kinase inhibitor imatinib mesylate. *J Clin Path* 57:215-217, 2004
87. **Reichardt P**, Pink D, Mrozek A, Lindner T, Hohenberger P. Gastrointestinale Stromatumoren (GIST). *Z Gastroenterol* 2004 (in press)